Best Practice & Research Clinical Haematology
Volume 22, Issue 1 , Pages 61-69, March 2009

Microparticles, thrombosis and cancer

  • Anat Aharon, PhD

      Affiliations

    • Thrombosis and Haemostasis Research Laboratory, Rambam Health Care Campus, P.O.B 9602, Haifa 31096, Israel
    • Corresponding Author InformationCorresponding author. Tel.: +972 4 8295201; Fax: +972 4 8543886.
  • ,
  • Benjamin Brenner, MD

      Affiliations

    • Thrombosis and Haemostasis Unit, Rambam Health Car Campus and the Rappaport Faculty of Medicine, Technion – Israel Institute of Technology, Haifa, Israel

Microvesicles comprised of exosomes and microparticles are shed from both normal and malignant cells upon cell activation or apoptosis. Microvesicles promote clot formation, mediate pro-inflammatory processes, facilitate cell-to-cell interactions, transfer proteins and mRNA to cells, and induce cell signalling. Microparticles bearing tissue factor play a central role in coagulation initiation and thrombus formation. This chapter will review earlier studies which focus on the role of procoagulant microvesicles in cancer thrombogenicity, and discuss the effects of microvesicles on vascular cell dysfunction and angiogenesis. In addition, this chapter will present new findings which characterize the haemostatic balance of microparticles, and suggest a method that may potentially serve to predict a state of hypercoagulability in cancer patients. This chapter highlights the interplay between microvesicles, coagulation factors and cancer.

Keywords: microparticles, microvesicles, cancer, thrombosis, tissue factor, angiogenesis

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1521-6926(08)00105-9

doi:10.1016/j.beha.2008.11.002

Best Practice & Research Clinical Haematology
Volume 22, Issue 1 , Pages 61-69, March 2009